| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.066 | 0.02 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.02 |